Implanet announces a highly successful capital increase with preemptive rights, raising €11.2 million

- Total demand amounted to €16.5m, i.e., an oversubscription rate of 170%
- Full exercise of the extension option - total size of the issue €11.2m

Bordeaux, March 18, 2015 – IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specialized in vertebral and knee-surgery implants, today announces a highly successful capital increase with preemptive rights, with gross proceeds totaling €11.2m, after full exercise of the extension clause.

Ludovic Lastennet, CEO of Implanet, says: “*The high level of demand for this capital increase illustrates the trust of both our shareholders and our new investors. The results of this capital increase place us in excellent position to accelerate the marketing of our range of JAZZ implants, to continue the reorganization of our teams – notably in the United States – by recruiting additional sales and marketing staff and to further our innovation efforts to complement our current range of implants. On behalf of the entire team, I would like to extend sincere thanks to our new shareholders, as well as to our longstanding shareholders, who have shown unwavering support since our IPO.*”

Following the subscription period, which closed on March 6, 2015, total demand amounted to €16.5m, up from initial amount of €9.7m, resulting in an oversubscription rate of 170%:

- 4,168,612 new shares were subscribed on an irreducible basis, accounting for 96.5% of the new shares to be issued;
- Subscription orders on a reducible basis accounted for 3,162,319 new shares.

Subsequently, the Company decided to fully exercise the extension option, representing an additional 15% of the initial offering size, thus taking the total number of new shares to be issued from 4,319,616 to 4,967,558. After exercise of this extension option, the gross proceeds of this offering, including the issue premium, amounts to €11.2m.

Following the capital increase, the Company’s share capital will amount to 15,550,620 euros, consisting of 10,367,080 shares with a par value of 1.5 euros each.

The settlement-delivery and admission to trading on the regulated market of Euronext in Paris of the new shares are scheduled to take place on March 20, 2015. These new shares will carry full dividend rights. They will be immediately fungible with the Company’s existing shares, and will be traded on the same trading line under ISIN code FR0010458729.

ODDO & Cie and SwissLife Banque Privée have acted as Joint Lead Managers and Bookrunners of the offering.
Information available to the public

The prospectus approved by the Autorité des marchés financiers (the “AMF”, the French Financial Markets Authority) on February 18, 2015 under number 15-055 consists of IMPLANET’s document de référence registered by the AMF on January 12, 2015 under number R.15-004, a note d’opération and a summary of the prospectus (included in the note d’opération).

Availability of the reference document - Copies of the prospectus are available free of charge from IMPLANET, Technopole Bordeaux Montesquieu, Allée François Magendie, 33650 Martillac, France (www.implanet.com) and from the AMF website (www.amf-france.org).

Risk factors – IMPLANET draws the public’s attention to chapter 4 (Risk Factors) of the document de référence registered by the AMF and to section 2 (Risk Factors) of the note d’opération.

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2014 sales of €7.0 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.

IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.
Ticker: IMPL - ISIN code: FR0010458729

Contacts

**IMPLANET**
Ludovic Lastennet
CEO
Tel.: +33 (0) 5 57 99 55 55
investors@implanet.com

**NewCap**
Investor Relations
Florent Alba
Tel.: +33 (0) 1 44 71 94 94
implanet@newcap.fr

Press Relations
Nicolas Mergeau
Tel.: +33 (0) 1 44 71 94 98
implanet@newcap.fr

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or purchase, nor the solicitation to sell or purchase Implant shares or Rights.

This press release and the prospectus registered with the French Financial Markets Authority (Autorité des marchés financiers) contain forward-looking statements. No guarantee is given as to these forecasts being achieved, which are subject to risks, including those described in the prospectus, and to the development of economic conditions, the financial markets and the markets in which Implant operates.

European Economic Area
The offer is open to the public in France.
With respect to members of the European Economic Area other than France (the “Member States”) that have implemented the Prospectus Directive,
no action has been undertaken or will be undertaken to make an offer to the public of securities requiring the publication of a prospectus in any Member State. Therefore, the Rights, the new shares and other securities mentioned in this press release may only be offered in Member States:

- to qualified investors as defined in the Prospectus Directive;
- to less than 100 or, if the Member State has transposed the relevant provision amending the Prospectus Directive, 150 natural or legal persons (other than qualified investors as defined in the Amending Prospectus Directive) per Member State; or
- in circumstances falling under the scope of Article 3 (2) of the Prospectus Directive.

For the purposes of this paragraph, (i) the expression “public offer of securities” in a given Member State means the communication to persons, in any form and by any means whatsoever, and containing sufficient information on the conditions of the offer and the securities to be offered to enable an investor to decide to purchase or subscribe said securities, as that definition has been, where appropriate, modified by the Member State in question, (ii) the expression “Prospectus Directive” means Directive 2003/71/EC of November 4, 2003, as transposed into the law of the Member State in question (as amended, including the Amending Prospectus Directive when it has been transposed by each Member State), and (iii) the expression “Amending Prospectus Directive” means Directive 2010/73/EU of the European Parliament and of the Council of November 24, 2010.

These sales restrictions relating to Member States apply in addition to any other restrictions applicable in Member States that have transposed the Prospectus Directive.

**United Kingdom**

This press release does not contain or constitute an invitation, inducement or solicitation to invest. This press release is intended solely for persons (i) who are not in the United Kingdom, (ii) who are investment professionals within the meaning of Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”), (iii) who are persons falling within the provisions of Article 49 (2) (a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Order, and (iv) who are persons to whom an invitation or inducement to engage in investment activity (within the meaning of the Financial Services and Markets Act 2000) may lawfully be made or caused to be made in the context of the issuance or sale of securities (all persons cited in (i), (ii), (iii) and (iv) together being designated as “Relevant Persons”).

This press release is aimed solely at Relevant Persons, and must not be used or relied upon by unauthorized persons. Any investment or investment activity in connection with this press release is reserved solely for Relevant Persons, and may only be made by Relevant Persons.

This press release does not constitute an approval by the Financial Services Authority or any other regulatory authority in the United Kingdom within the meaning of Section 85 of the Financial Services and Markets Act 2000.

**United States of America**

This press release does not constitute an offer to sell securities or the solicitation of an offer to purchase securities in the United States of America. The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States in the absence of registration or an exemption from registration under the Securities Act. Implant does not intend to register the offer in whole or in part in the United States of America, or to make a public offer in the United States of America.

**Canada, Australia and Japan**

The new shares and Rights may not be offered, sold or purchased in Canada, Australia or Japan.